Thymic Carcinoma Clinical Trial
Official title:
Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas
This is a non-randomized clinical trial in patients with thymic carcinomas who failed prior systemic therapy. All subjects will receive pembrolizumab and epacadostat treatment in three week cycles until unacceptable toxicity, death, progressive disease or withdrawal.
The amended phase II study of pembrolizumab and epacadostat is for thymic carcinoma patients who recurred after at least one prior chemotherapy regimen. The primary endpoint is response rate; secondary endpoints are Progression-Free Survival, Overall Survival and treatment tolerability. Responses will be assessed according to RECIST 1.1; progression-free survival is defined as time between start of treatment and tumor progression or death; survival is the time between start of treatment and death. Furthermore exploratory studies will be performed on archival tumor material (PDL-1 expression, next-generation sequencing), and fresh biopsies (culturing; next-generation sequencing). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06019468 -
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
|
Phase 2 | |
| Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
| Completed |
NCT02623127 -
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
| Recruiting |
NCT06248515 -
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
|
Phase 2 | |
| Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03449173 -
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
|
Phase 2 | |
| Recruiting |
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT01364727 -
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
|
Phase 2 | |
| Suspended |
NCT03463460 -
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
|
Phase 2 | |
| Completed |
NCT00010257 -
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
|
Phase 2 | |
| Completed |
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 | |
| Active, not recruiting |
NCT03583086 -
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03517488 -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00198133 -
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT03170804 -
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
|
N/A | |
| Recruiting |
NCT05667948 -
Molecular Analysis and Treatment Options of Thymic Malignancies
|
||
| Terminated |
NCT01011439 -
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
|
Phase 2 | |
| Terminated |
NCT01143545 -
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
|
Phase 1 | |
| Completed |
NCT02307500 -
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
|
Phase 2 |